Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular m...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Kconn52 Aug. 18 at 12:32 PM

$FBIOP For those of you who are wondering about the potential timing of restoration of the dividend on this security, here are the relevant dates. Even if a material default is subsequently cured or waived, the issuer remains ineligible to use Form S-3 during the period between the date of the default and the filing of the audited financial statements for that fiscal year. So, FBIO would have to cure the default before 12-31-2026 to be eligible, after the filing of the FY2026 audited financials indicating that the default had been cured, to use an ATM during 2027.

1 · Reply

1000kv Aug. 15 at 4:26 PM

$FBIOP I asked Claude to look through the 10 q and compare to my earlier model of cash flow. One note that was called out was in the notes to the financial statements and may impact the timing yet of the reinstatement. "In July 2026, Cyprium declared a cash dividend of approximately $118.6 million, of which approximately $95.4 million was payable to Fortress." I feel a little better on timing, but I think an announcement by the end of q-3 reporting is getting important to make the timeline for reinstatement of ATM next year. Just an opinion, please do your own DD. If anyone has a different take on the way this works, please update with your thoughts.

1 · Reply

FinSUN Aug. 14 at 10:44 PM

$FBIOP $FBIO debt holders first, then insiders... and insiders want OUT... the whole Fortress capital and business shenanigan is all about sell to a third party... damn, it's the entire principle business model... When they sell.. and they will sell, they will convert, get the majority of the company, vote YES to an acquisition that is convenient to them and retire... by the time that happens they will the interest due to preferred will obliterate any current commons' OS number... Maybe selling to someone that will repeat the game... rinse and repeat. All you can do is trade. The ultimate game of this play is NOT shareholderd value, not the way you would expect from a public company. If you don't get this you will waste years and grow bitter. Understanding the capital structure, the governance and the incentives is 90% of the game in stocks like this.. the other 10% is knowing how to trade a manipulated and structurally drugged small cap, like many others.

1 · Reply

FinSUN Aug. 14 at 10:35 PM

$FBIOP still waiting on those dividends ? 😂

0 · Reply

makrodimutross Aug. 14 at 5:35 PM

$FBIO $FBIOP One of these EITHER OR conditions were met at the time of the PRV Sale. (Positive net assets) The other condition (Net profits) is on track to be met by next year. "Fiduciary duty to common shareholders" is a joke. Was it "fiduciary duty" to pay down the Oaktree Loan? Resoundingly, YES. Likewise, it would also be considered "fiduciary duty" to pay the arrears owed to preferred stockholders. They simply don't care, and refuse to communicate with earnings calls, or even reply to emails from concerned investors. The only acceptable answer to this would be if they are negotiating with potential partners, and in possession of significant definitive material non-public information.

1 · Reply

thesaltier1 Aug. 14 at 4:38 PM

$FBIOP reminds me of a tenant that drives a nice car, eats out all the time, but refuses to pay rent, pay what you owe and dont shaft the people who gave you money originally, management not addressing some sort of guidance on the preferred reinstatement is incompetence in not realizing the impact on shareholders, what if you bought these years ago expecting reliable monthly income based on what management promised?

0 · Reply

hafstein Aug. 14 at 4:34 PM

$FBIO $FBIOP This shitty company with old ceo has been neglecting shareholders for the last 16 years. All the time. Short this shit 💩

0 · Reply

Pharm_Hand Aug. 14 at 3:04 PM

$FBIO There's zero tute ownership in $FBIOP. Begs the question as to why Wall St is fucking around so hard with this.

1 · Reply

makrodimutross Aug. 14 at 2:43 PM

$FBIO $FBIOP this is what happens when the company shows absolutely no interest in developing a plan to make good on the cash they owe to preferred stockholders. This company deserves to be shorted into the fucking ground until they make good to those higher in the capital structure.

1 · Reply

makrodimutross Aug. 13 at 9:40 PM

$FBIOP $FBIO Quick refresher on the milestone payments due to Cyprium for ZYCUBO sales: Given 0.3m royalty payments from ZYCUBO, we can assume that 10m in revenues were realized in the first 6 months of launching. The first milestone payment of 2.5m triggers at 75m in yearly sales (75m in yearly sales produces an additional 2.25m in royalties) The 2nd milestone payment of 12.5m triggers at 125m in yearly sales (royalty payment bumps from 3% to 12% if sales exceed 100m, 15m in royalties) The 3rd milestone payment of 17.5m triggers at 175m in yearly sales (175m in yearly sales produces an additional 21m in royalties) The 4th milestone payment of 20m triggers at 200m in yearly sales (200m in yearly sales produces an additional 24m in royalties) The 5th milestone payment of 37.5m triggers at 300m in yearly sales (300m in yearly sales produces an additional 36m in royalties) The 6th milestone payment of 37.5m triggers at 400m in yearly sales (+ 48m in royalties)

2 · Reply

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Fortress Biotech Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Fortress Biotech Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Fortress Biotech Quarterly report: Q2 2026

Aug 12, 2026, 4:01 PM EDT - 6 days ago

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A